Related Experiment Videos
[Correlation of lipoprotein(a) and ischemic heart disease]
1Kardiológiai Osztály, MAV Kórház, Budapest. kalinaak@axelero.hu
Insights
High lipoprotein(a) [Lp(a)] levels increase coronary heart disease risk. Lowering low-density lipoprotein (LDL) is the most effective strategy for managing elevated Lp(a) concentrations.
Area of Science:
- Cardiovascular Science
- Lipid Metabolism
- Atherosclerosis Research
Context:
- Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for coronary heart disease (CHD).
- High Lp(a) contributes to atherothrombosis via impaired fibrinolysis and arterial cholesterol deposition.
- Lp(a)'s atherogenicity is linked to its structural similarity with thrombohemostatic factors.
Purpose:
- To review the role of lipoprotein(a) [Lp(a)] in coronary heart disease (CHD).
- To discuss the mechanisms by which Lp(a) contributes to atherothrombotic risk.
- To evaluate therapeutic options for managing elevated Lp(a) levels.
Summary:
- Plasma lipoprotein(a) [Lp(a)] concentration is genetically determined and unaffected by common risk factors.
- Few medications effectively lower Lp(a) without significant side effects.
- Lowering low-density lipoprotein (LDL) is identified as the optimal therapeutic approach for elevated Lp(a).
Impact:
- Provides insights into the atherogenic mechanisms of lipoprotein(a) [Lp(a)].
- Highlights the limitations of current pharmacological interventions for Lp(a) reduction.
- Recommends LDL reduction as the primary strategy for managing elevated Lp(a) and mitigating CHD risk.
Abstract:
Increased plasma levels of lipoprotein(a) [Lp(a)] have been considered an independent risk factor for coronary heart disease (CHD). A high concentration of Lp(a) contributes to atherothrombotic risk by multiple mechanisms that include impaired fibrinolysis and increased cholesterol deposition in the arterial wall. Its atherogenicity seems to be related to the similarity in structure with thrombohemostatic factors. The level of Lp(a) in plasma is genetically determined and appears to be unaffected by usual risk factors. There are few medications which have been shown to lower the plasma concentration of Lp(a), however, since these drugs all have multiple other effects their, use is not the choice of the therapy. According to the results of examinations, the best therapeutic option for increased plasma Lp(a) concentration is to lower the plasma level of LDL.